Efficacy and safety of the single-dose pegylated G-CSF vs. daily G-CSF for peripheral blood stem cells mobilization in donors: a multicenter, randomized controlled trial - Scorecard - MDSpire
Advertisement
Efficacy and safety of the single-dose pegylated G-CSF vs. daily G-CSF for peripheral blood stem cells mobilization in donors: a multicenter, randomized controlled trial
Clinical Scorecard: Comparative Analysis of Single-Dose Pegylated G-CSF Versus Daily G-CSF for Mobilizing Peripheral Blood Stem Cells in Donors: Results from a Multicenter, Randomized Controlled Study
At a Glance
Category
Detail
Condition
Peripheral Blood Stem Cell Mobilization
Key Mechanisms
Pegylated G-CSF offers a longer half-life and reduces the need for daily injections compared to traditional G-CSF.
Target Population
Healthy donors aged 18-55 years related to allo-HSCT recipients.
Care Setting
Multicenter, randomized controlled trial
Key Highlights
83.3% of donors in the Peg-G-CSF group collected ≥4×10^6 CD34+ cells/kg recipient weight.
The median yield of CD34+ cells was comparable between Peg-G-CSF and G-CSF groups.
No significant difference in side effects, engraftment, GVHD, or survival between groups.
Guideline-Based Recommendations
Diagnosis
Eligible donors must be related to allo-HSCT recipients and meet specific health criteria.
Management
Administer 12 mg Peg-G-CSF as a single dose or 10 µg/kg/d G-CSF daily for mobilization.
Monitoring & Follow-up
Monitor CD34+ cell counts, adverse events, and outcomes in recipients post-transplant.
Risks
Potential side effects similar between Peg-G-CSF and G-CSF; monitor for GVHD and other complications.
Patient & Prescribing Data
Healthy donors aged 18-55 years with normal organ function and negative infectious disease tests.
Peg-G-CSF provides a single-dose alternative to daily G-CSF with comparable efficacy.
Clinical Best Practices
Follow ethical guidelines and obtain informed consent from all participants.
Ensure rigorous monitoring of donor health and recipient outcomes.
